Analysis of CDO1 , PITX2 , and CDH13 Gene Methylation in Early Endometrial Cancer for Prediction of Medical Treatment Outcomes.

Autor: Krasnyi AM; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia., Gadzhieva LT; Moscow Multidisciplinary Clinical Center 'Kommunarka', 108814 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia., Kokoeva DN; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia., Kosenko MG; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia., Yarotskaya EL; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia., Pavlovich SV; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia., Ashrafyan LA; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia., Sukhikh GT; V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, 117198 Moscow, Russia.; I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia.
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 30; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 30.
DOI: 10.3390/ijms25094892
Abstrakt: An observational cohort study of patients diagnosed with endometrial cancer (EC) stage IA G1, or atypical endometrial hyperplasia (AEH), undergoing organ-preserving treatment, was conducted.
Objective of the Study: To determine CDO1 , PITX2 , and CDH13 gene methylation levels in early endometrial cancer and atypical hyperplasia specimens obtained before organ-preserving treatment in the patients with adequate response and with insufficient response to hormonal treatment.
Materials and Methods: A total of 41 endometrial specimens obtained during diagnostic uterine curettage in women with EC ( n = 28) and AEH ( n = 13), willing to preserve reproductive function, were studied; 18 specimens of uterine cancer IA stage G1 from peri- and early postmenopausal women (comparison group) were included in the study. The control group included 18 endometrial specimens from healthy women obtained by diagnostic curettage for missed abortion and/or intrauterine adhesions. Methylation levels were analyzed using the modified MS-HRM method.
Results: All 13 women with AEH had a complete response (CR) to medical treatment. In the group undergoing organ-preserving treatment for uterine cancer IA stage G1 ( n = 28), 14 patients had a complete response (EC CR group) and 14 did not (EC non-CR group). It was found that all groups had statistically significant differences in CDO1 gene methylation levels compared to the control group ( p < 0.001) except for the EC CR group ( p = 0.21). The p -value for the difference between EC CR and EC non-CR groups was <0.001. The differences in PITX2 gene methylation levels between the control and study groups were also significantly different ( p < 0.001), except for the AEH group ( p = 0.21). For the difference between EC CR and EC non-CR groups, the p -value was 0.43. For CDH13 gene methylation levels, statistically significant differences were found between the control and EC non-CR groups ( p < 0.001), and the control and EC comparison groups ( p = 0.005). When comparing the EC CR group with EC non-CR group, the p -value for this gene was <0.001. The simultaneous assessment of CDO1 and CDH13 genes methylation allowed for an accurate distinction between EC CR and EC non-CR groups (AUC = 0.96).
Conclusion: The assessment of CDO1 and CDH13 gene methylation in endometrial specimens from patients with endometrial cancer (IA stage G1), scheduled for medical treatment, can predict the treatment outcome.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje